AR080108A1 - A STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION THAT INCLUDES 4-AMINO-1 - [(2R, 5S) -2- (HYDROXIMETHYL) -1,3-OXATIOLAN-5-IL] -1,2-DIHYDROPIRIMIDINE-2-ONA, ACID ({[(2R) -1- (6-AMINO-9H-PURINA-9-IL) PROPAN-2-IL] OXI} METHYL) PHOSPHORIC AND 8-CHLORINE-5- (2-CYCLOPROPYLETINYL) -5- (TRIFLUOROMETIL ) -4-OXA-2-AZABICI - Google Patents
A STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION THAT INCLUDES 4-AMINO-1 - [(2R, 5S) -2- (HYDROXIMETHYL) -1,3-OXATIOLAN-5-IL] -1,2-DIHYDROPIRIMIDINE-2-ONA, ACID ({[(2R) -1- (6-AMINO-9H-PURINA-9-IL) PROPAN-2-IL] OXI} METHYL) PHOSPHORIC AND 8-CHLORINE-5- (2-CYCLOPROPYLETINYL) -5- (TRIFLUOROMETIL ) -4-OXA-2-AZABICIInfo
- Publication number
- AR080108A1 AR080108A1 ARP110100345A AR080108A1 AR 080108 A1 AR080108 A1 AR 080108A1 AR P110100345 A ARP110100345 A AR P110100345A AR 080108 A1 AR080108 A1 AR 080108A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino
- propan
- oxa
- phosphoric
- methyl
- Prior art date
Links
Abstract
Una composicion farmacéutica estable de administracion oral en forma de una unica unidad de dosis caracterizada porque comprende un nucleosido inhibidor de la transcriptasa reversa, un nucleotido inhibidor de la transcriptasa reversa, un inhibidor de la transcriptasa reversa no nucleosídico y uno o más excipientes farmacéuticamente aceptables. Un procedimiento para la fabricacion de un comprimido multigranulado recubierto. El uso de la combinacion de 4-amino-1-[(2R,5S)-2-(hidroximetil)-1,3-oxatiolan-5-il]-1,2-dihidropirimidina-2-ona, acido ({[(2R)-1-(6-amino-9H-purina-9-il)propan-2-il]oxi}metil) fosforico y 8-cloro-5-(2-ciclopropiletinil)-5- (trifluorometil)-4-oxa-2-azabiciclo[4.4.0] deca-7,9,11-trien-3-ona para la manufactura de un medicamento para el tratamiento de infecciones virales, particularmente infecciones retrovirales que incluye el virus de inmunodeficiencia humana (HIV) o prevencion de los síntomas o efectos de una infeccion por HIV o consecuencia de la misma, en un individuo infectado. Un método de tratamiento que lo utiliza.A stable pharmaceutical composition for oral administration in the form of a single dose unit characterized in that it comprises a reverse transcriptase inhibitor nucleoside, a reverse transcriptase inhibitor nucleotide, a non-nucleoside reverse transcriptase inhibitor and one or more pharmaceutically acceptable excipients. A process for the manufacture of a multigranulated coated tablet. The use of the combination of 4-amino-1 - [(2R, 5S) -2- (hydroxymethyl) -1,3-oxathiolan-5-yl] -1,2-dihydropyrimidine-2-one, acid ({[ (2R) -1- (6-amino-9H-purine-9-yl) propan-2-yl] oxy} methyl) phosphoric and 8-chloro-5- (2-cyclopropylethynyl) -5- (trifluoromethyl) -4 -oxa-2-azabicyclo [4.4.0] deca-7,9,11-trien-3-one for the manufacture of a medicament for the treatment of viral infections, particularly retroviral infections including human immunodeficiency virus (HIV) or prevention of the symptoms or effects of an HIV infection or consequence thereof, in an infected individual. A treatment method that uses it.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP110100345 AR080108A1 (en) | 2011-02-01 | 2011-02-01 | A STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION THAT INCLUDES 4-AMINO-1 - [(2R, 5S) -2- (HYDROXIMETHYL) -1,3-OXATIOLAN-5-IL] -1,2-DIHYDROPIRIMIDINE-2-ONA, ACID ({[(2R) -1- (6-AMINO-9H-PURINA-9-IL) PROPAN-2-IL] OXI} METHYL) PHOSPHORIC AND 8-CHLORINE-5- (2-CYCLOPROPYLETINYL) -5- (TRIFLUOROMETIL ) -4-OXA-2-AZABICI |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP110100345 AR080108A1 (en) | 2011-02-01 | 2011-02-01 | A STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION THAT INCLUDES 4-AMINO-1 - [(2R, 5S) -2- (HYDROXIMETHYL) -1,3-OXATIOLAN-5-IL] -1,2-DIHYDROPIRIMIDINE-2-ONA, ACID ({[(2R) -1- (6-AMINO-9H-PURINA-9-IL) PROPAN-2-IL] OXI} METHYL) PHOSPHORIC AND 8-CHLORINE-5- (2-CYCLOPROPYLETINYL) -5- (TRIFLUOROMETIL ) -4-OXA-2-AZABICI |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080108A1 true AR080108A1 (en) | 2012-03-14 |
Family
ID=45830843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100345 AR080108A1 (en) | 2011-02-01 | 2011-02-01 | A STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION THAT INCLUDES 4-AMINO-1 - [(2R, 5S) -2- (HYDROXIMETHYL) -1,3-OXATIOLAN-5-IL] -1,2-DIHYDROPIRIMIDINE-2-ONA, ACID ({[(2R) -1- (6-AMINO-9H-PURINA-9-IL) PROPAN-2-IL] OXI} METHYL) PHOSPHORIC AND 8-CHLORINE-5- (2-CYCLOPROPYLETINYL) -5- (TRIFLUOROMETIL ) -4-OXA-2-AZABICI |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR080108A1 (en) |
-
2011
- 2011-02-01 AR ARP110100345 patent/AR080108A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2009002857A (en) | SOLID PHARMACEUTICAL PRESENTATION FORMS OF ORAL ADMINISTRATION WITH QUICK RELEASE OF ACTIVE PRINCIPLE | |
| AR065731A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING 2- [6- (3-AMINO-PIPENIDIN-1-IL) -3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PRIMIDIN-1-IL METHYL] -4-FLUORO -BENZONITRILE. USE. TREATMENT METHOD, WEEKLY ADMINISTRATION OF DIPEPTIDILPEPTIDASA INHIBITORS. | |
| JP2016508134A5 (en) | ||
| HRP20211543T1 (en) | Quinazoline derivatives used to treat hiv | |
| EA201171376A1 (en) | THYENO DERIVATIVES [2,3-B] PIRIDINE AS VIRUS REPLICATION INHIBITORS | |
| CY1118183T1 (en) | PHARMACEUTICAL FORM THAT CONTAINS NIFEDIPIN OR NISOLDIPIN AND AN ANGIOTENSIN II COMPONENT / AND A DIRECTIVE | |
| CY1114215T1 (en) | PHARMACEUTICAL SOLUTIONS FOR SOLID PRESSURE INHIBITORS | |
| CY1124914T1 (en) | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN INTEGRATION INHIBITOR | |
| SI2932970T1 (en) | Antiviral therapy | |
| JP2015038149A5 (en) | ||
| CO2018004776A2 (en) | Therapeutic compositions for the treatment of human immunodeficiency virus | |
| MX2012007410A (en) | Novel antiviral compounds. | |
| AR067184A1 (en) | USE OF 6- (3-CHLORO-2-FLUORBENCIL) -1 - [(2S) -1-HIDROXI-3-METILBUTAN-2-IL] -7-METOXI-4-OXO-1,4-DIHYDROCHINOLINE-3- CARBOXILICO. PHARMACEUTICAL COMPOSITION | |
| NZ602670A (en) | Non-nucleoside reverse transcriptase inhibitors | |
| EA201491479A1 (en) | DERIVATIVES OF LUPANOV TRITERPENOIDS AND THEIR PHARMACEUTICAL APPLICATIONS | |
| CO2021008988A2 (en) | Combination of dextromethorphan and bupropion for the treatment of depression | |
| EA200870183A1 (en) | LONG-TERM TREATMENT OF HIV INFECTION | |
| AR070026A1 (en) | SET OF ELEMENTS FOR THE DOSAGE OF 1-AMINO-ALQUILCICLOHEXANOS, SUCH AS NERAMEXAN, AND TREATMENT OF DIFFERENT DISEASES INCLUDING TINNITUS | |
| RU2009111378A (en) | THERAPEUTIC COMPOSITIONS CONTAINING SPECIFIC ANTAGONIST OF AN ENDOTHELIN RECEPTOR AND PDE5 INHIBITORS | |
| RU2016142611A (en) | MEDICINAL PRODUCTS FOR HIV REVERSE TRANSCRIPTASE INHIBITORS | |
| RU2014139825A (en) | Derivatives of Ingenols for the Reactivation of the Latent HIV Virus | |
| BR112012024522A2 (en) | combination, use of a combination, pharmaceutical composition, single dosage form, kit, and method for treating a disorder | |
| AR080108A1 (en) | A STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION THAT INCLUDES 4-AMINO-1 - [(2R, 5S) -2- (HYDROXIMETHYL) -1,3-OXATIOLAN-5-IL] -1,2-DIHYDROPIRIMIDINE-2-ONA, ACID ({[(2R) -1- (6-AMINO-9H-PURINA-9-IL) PROPAN-2-IL] OXI} METHYL) PHOSPHORIC AND 8-CHLORINE-5- (2-CYCLOPROPYLETINYL) -5- (TRIFLUOROMETIL ) -4-OXA-2-AZABICI | |
| PH12014501601A1 (en) | Artemisinin-based combination therapy for treating viral mediated disease | |
| CO2020000292A2 (en) | Combined medicinal preparation to treat viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |